Salarius Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Salarius Pharmaceuticals's estimated annual revenue is currently $2.8M per year.
- Salarius Pharmaceuticals's estimated revenue per employee is $232,500
Employee Data
- Salarius Pharmaceuticals has 12 Employees.
- Salarius Pharmaceuticals grew their employee count by -50% last year.
Salarius Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | SVP, Clinical Development | Reveal Email/Phone |
4 | VP, Chemistry, Manufacturing and Control | Reveal Email/Phone |
5 | Executive Director, CMC | Reveal Email/Phone |
6 | Director Targeted Protein Degradation Development | Reveal Email/Phone |
Salarius Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Salarius Pharmaceuticals?
Salarius Pharmaceuticals (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet medical need, with an ongoing clinical study in Ewing sarcoma and a clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT)
keywords:N/AN/A
Total Funding
12
Number of Employees
$2.8M
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 12 | -14% | N/A |
#2 | $1M | 12 | N/A | N/A |
#3 | $1.2M | 12 | N/A | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |